PYXS Pyxis Oncology, Inc.
Financings ·
Pyxis Oncology is selling 36,047,919 shares at $2.900 and pre-funded warrants, with common warrants at $3.50 that cannot be exercised until stockholders approve more authorized shares. Its auditor's report on the 2025 financial statements carries a going-concern warning.
Pyxis Oncology agreed to sell 19,600,153 shares at $2.551 and warrants at $3.289 to investors led by BVF Partners L.P. The press release says the upfront money extends cash into the second quarter of 2027, while the company's annual report carried a going-concern warning and said cash would fund operations only into the fourth quarter of 2026.
Pyxis Oncology is a clinical-stage oncology company developing treatments for solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Its lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B of fibronectin (EDB+FN), a component of the tumor microenvironment. The company describes a three-part mechanism in which the released payload kills cancer cells directly, spreads to nearby cancer cells through a bystander effect, and triggers immunogenic cell death. MICVO is being studied as a monotherapy in recurrent and metastatic HNSCC and in combination with KEYTRUDA (pembrolizumab) in first-line and later-line recurrent and metastatic HNSCC and other solid tumors. A Phase 1 monotherapy dose expansion began in January 2025 at 5.4 mg/kg. The combination study, PYX-201-102, is a Phase 1/2 trial that is actively enrolling. Merck & Co., Inc. (Merck) provides KEYTRUDA under a Clinical Trial Collaboration and Supply Agreement with the company.
| Product or program | What it is | Stage |
|---|---|---|
| Micvotabart pelidotin (MICVO, formerly PYX-201) | Antibody-drug conjugate targeting extradomain-B of fibronectin in solid tumors | Phase 1 monotherapy dose expansion (Part 2) in R/M HNSCC |
| MICVO with KEYTRUDA (PYX-201-102) | Combination study of MICVO with pembrolizumab in advanced solid tumors | Phase 1/2, actively enrolling |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $13.9 million | $16.1 million |
| Research and development | $73.7 million | $58.7 million |
| Net income (loss) | -$79.6 million | -$77.3 million |
| Cash from operations | -$63.5 million | -$57.7 million |
| Cash and equivalents | $15.4 million | $19.5 million |
| Short-term investments | $51.4 million | $107.5 million |
Our latest story on this, dated Sep 29, 2026: "Pyxis Oncology prices $109,998,133 stock and warrant offering at $2.90". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 29, 2026: "Pyxis Oncology prices $109,998,133 stock and warrant offering at $2.90". The story links the filing or release it is based on. Read the story.
Pyxis Oncology, Inc. trades under the ticker PYXS on NASDAQ.
Pyxis Oncology, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Pyxis Oncology, Inc. is 1782223. Its filings are on SEC EDGAR.
83,408,050 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Pyxis Oncology, Inc. under United States.
Our directory classifies Pyxis Oncology, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Pyxis Oncology, Inc. is US7473241013.
aibio.space lists Pyxis Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Pyxis Oncology is a clinical-stage oncology company developing treatments for solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Its lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B of fibronectin (EDB+FN), a component of the tumor microenvironment.
Micvotabart pelidotin (MICVO, formerly PYX-201): Antibody-drug conjugate targeting extradomain-B of fibronectin in solid tumors Stage: Phase 1 monotherapy dose expansion (Part 2) in R/M HNSCC.
MICVO with KEYTRUDA (PYX-201-102): Combination study of MICVO with pembrolizumab in advanced solid tumors Stage: Phase 1/2, actively enrolling.
$13.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio